Truist Securities Maintains Buy on PTC Therapeutics, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Barry Jonas has maintained a 'Buy' rating on PTC Therapeutics (NASDAQ:PTCT), but lowered the price target from $60 to $45.

September 18, 2023 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
PTC Therapeutics' price target has been lowered from $60 to $45 by Truist Securities, though the 'Buy' rating is maintained.
The lowering of the price target by Truist Securities could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could offset some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100